The main mechanism of action described for bortezomib in MM is proteasome inhibition which results in endoplasmic reticulum stress-induced apoptosis, accumulation of ROS, and deregulation of functional proteins (such as IL-6, TNF-α, NF-κB) (85). The gene discussed is NFKB1; the disease is Miyoshi myopathy.